{"title":"An Overview of Currently Available Injectable Therapies in Diabetes: A Guide to Practitioners.","authors":"Jothydev Kesavadev, Anjana Basanth, Arun Shankar, Banshi Saboo, Anjana Ranjit Mohan, Shashank Joshi, Sujoy Ghosh, Gopika Krishnan, Krishnadev Jothydev, Asha Ashik","doi":"10.1007/s12325-025-03250-3","DOIUrl":null,"url":null,"abstract":"<p><p>The management of diabetes has seen significant advancements with the introduction of various injectable therapies. Being a common chronic disorder, it is managed by doctors across all specialties worldwide. Despite the availability of new medications, healthcare professionals continue to face ambiguity due to differing terminologies and variations in regional practices. This review aims to elucidate the current therapeutic spectrum of injectable therapies in diabetes care, providing clarity on the types, mechanisms, and clinical implications of both insulin and non-insulin injections. An extensive review of existing literature was conducted, focusing on insulin injections (including short-acting, rapid-acting, ultra-rapid acting, intermediate-acting, long acting and ultra-long-acting types), non-insulin injections (such as glucagon-like peptide-1 [GLP-1] receptor agonists, dual GLP-1 and gastric inhibitory polypeptide [GIP] agonist, and amylin analogs) and co-formulations (long-acting insulin with GLP-1 or long-acting insulin with rapid acting insulin). We have included innovators and biosimilars in this review article for better understanding. Insulin therapies offer tailored glycemic control, while non-insulin injectables provide additional benefits in weight management and reduced hypoglycemia risk. This review serves as a comprehensive guide for healthcare providers worldwide to navigate the landscape of injectable treatment options in diabetes, with a focus on optimizing therapeutic outcomes through informed decision-making.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12325-025-03250-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
The management of diabetes has seen significant advancements with the introduction of various injectable therapies. Being a common chronic disorder, it is managed by doctors across all specialties worldwide. Despite the availability of new medications, healthcare professionals continue to face ambiguity due to differing terminologies and variations in regional practices. This review aims to elucidate the current therapeutic spectrum of injectable therapies in diabetes care, providing clarity on the types, mechanisms, and clinical implications of both insulin and non-insulin injections. An extensive review of existing literature was conducted, focusing on insulin injections (including short-acting, rapid-acting, ultra-rapid acting, intermediate-acting, long acting and ultra-long-acting types), non-insulin injections (such as glucagon-like peptide-1 [GLP-1] receptor agonists, dual GLP-1 and gastric inhibitory polypeptide [GIP] agonist, and amylin analogs) and co-formulations (long-acting insulin with GLP-1 or long-acting insulin with rapid acting insulin). We have included innovators and biosimilars in this review article for better understanding. Insulin therapies offer tailored glycemic control, while non-insulin injectables provide additional benefits in weight management and reduced hypoglycemia risk. This review serves as a comprehensive guide for healthcare providers worldwide to navigate the landscape of injectable treatment options in diabetes, with a focus on optimizing therapeutic outcomes through informed decision-making.
期刊介绍：
Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
